Aryl bis(diazeniumdiolates): Potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 7944-7952

  Andrei, Daniela ^a,c   Maciag, Anna E ^b   Chakrapani, Harinath ^a   Citro, Michael L ^b   Keefer, Larry K ^a   Saavedra, Joseph E ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c DOMINICAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 (N,N DIMETHYLAMINO)DIAZEN 1 IUM 1,2 DIOL 2 ATO] 2,4 DINITRO 5 [(2 HYDROXYMETHYLPYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOL 2 ATO]BENZENE; 1 [1 (N,N DIMETHYLAMINO)DIAZEN 1 IUM 1,2 DIOL 2 ATO] 2,4 DINITRO 5 [[(4 ETHOXYCARBONYL)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOL 2 ATO]BENZENE; 1 [4 (ETHOXYCARBONYL)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOL 2 ATO] 2,4 DINITRO 5 [[4 (N,N DIETHYLAMINOCARBONYL)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOL 2 ATO]BENZENE; 2 O [2,4 DINITRO 5 [4 (N METHYLAMINO)BENZOYLOXY]PHENYL] 1 (N,N DIMETHYLAMINO)DIAZEN 1 IUM 1,2 DIOLATE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BIS(DIAZENIUMDIOLATE); CELL PROTEIN; GLUTATHIONE; NITRIC OXIDE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NITROSATIVE STRESS;

AZO COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTATHIONE; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; NITRIC OXIDE; NITRIC OXIDE DONORS; PRODRUGS;

EID: 58149085628     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800831y     Document Type: Article

References (45)

1. Ignarro, L. J.; Cirino, G.; Casini, A.; Napoli, C. Nitric oxide as a signaling molecule in vascular system: An overview. J. Cardiovasc. Pharmacol. 1999, 34, 879-886.
2. Ignarro, L. J. Nitric oxide: a unique endogenous signaling molecule in vascular biology (Nobel lecture). Angew. Chem., Int. Ed. 1999, 38, 1882-1892.
3. Moncada, S.; Herman, A. G.; Vanhoutte, P. Endothelium-derived relaxing factor is identified as nitric oxide. Trends Pharmacol. Sci. 1987, 8, 365-368.
4. Moncada, S.; Radomski, M. W.; Palmer, R. M. J. Endothelium-derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem. Pharmacol. 1988, 37, 2495-2501.
5. Moncada, S.; Palmer, R. M. J.; Higgs, E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991, 43, 109-142.
6. Murad, F. Discovery of some of the biological effects of nitric oxide and its role in cell signaling (Nobel lecture). Angew. Chem., Int. Ed. 1999, 38, 1856-1868.
7. Bonavida, B.; Khineche, S.; Huerta-Yepez, S.; Garbán, H. Therapeutic potential of nitric oxide in cancer. Drug Resist. Updates 2006, 9, 157-173.
8. Magrinat, G.; Mason, S. N.; Shami, P. J.; Weinberg, J. B. Nitric oxide modulation of human leukemia cell differentiation and gene expression. Blood 1992, 80, 1880-1884.
9. Shami, P. J.; Moore, J. O.; Gockerman, J. P.; Hathorn, J. W.; Misukonis, M. A.; Weinberg, J. B. Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells. Leuk. Res. 1995, 19, 527-533.
10. Shami, P. J.; Sauls, D. L.; Weinberg, J. B. Schedule and concentration-dependent induction of apoptosis in leukemia cells by nitric oxide. Leukemia 1998, 12, 1461-1466.
11. Weinberg, J. B.; Misukonis, M. A.; Shami, P. J.; Mason, S. N.; Sauls, D. L.; Dittman, W. A.; Wood, E. R.; Smith, G. K.; McDonald, B.; Bachus, K. E.; Haney, A. F.; Granger, D. L. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995, 86, 1184-1195.
12. Keefer, L. K.; Nims, R. W.; Davies, K. M.; Wink, D. A. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol. 1996, 268, 281-293.
13. Keefer, L. K. Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities. Curr. Top. Med. Chem. 2005, 5, 625-636.
14. Scatena, R.; Bottoni, P.; Martorana, G. E.; Giardina, B. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin. Invest. Drugs 2005, 14, 835-846.
15. King, S. B. Mechanisms and novel directions in the biological applications of nitric oxide donors. Free Radical Biol. Med. 2004, 37, 735-736.
16. Thatcher, G. R. J. An introduction to NO-related therapeutic agents. Curr. Top. Med. Chem. 2005, 5, 597-601.
17. Kiziltepe, T.; Hideshima, T.; Ishitsuka, K.; Ocio, E. M.; Raje, N.; Catley, L.; Li, C. Q.; Trudel, L. J.; Yasui, H.; Vallet, S.; Kutok, J. L.; Chauhan, D.; Mitsiades, C. S.; Saavedra, J. E.; Wogan, G. N.; Keefer, L. K.; Shami, P. J.; Anderson, K. C. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 2007, 110, 709-718.
18. Liu, J.; Li, C.; Qu, W.; Leslie, E.; Bonifant, C. L.; Buzard, G. S.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol. Cancer Ther. 2004, 3, 709-714.
19. Ren, Z.; Kar, S.; Wang, Z.; Wang, M.; Saavedra, J. E.; Carr, B. I. JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways. J. Cell. Physiol 2003, 197, 426-434.
20. 2-aryl diazeniumdiolates in vitro and in vivo. J. Med. Chem. 2006, 49, 4356-4366.
21. Shami, P. J.; Saavedra, J. E.; Wang, L. Y.; Bonifant, C. L.; Diwan, B. A.; Singh, S. V.; Gu, Y.; Fox, S. D.; Buzard, G. S.; Citro, M. L.; Waterhouse, D. J.; Davies, K. M.; Ji, X.; Keefer, L. K. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol. Cancer Ther. 2003, 2, 409-417.
22. Udupi, V.; Yu, M.; Malaviya, S.; Saavedra, J. E.; Shami, P. J. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells. Leuk. Res. 2006, 30, 1279-1283.
23. Saavedra, J. E.; Srinivasan, A.; Buzard, G. S.; Davies, K. M.; Waterhouse, D. J.; Inami, K.; Wilde, T. C.; Citro, M. L.; Cuellar, M.; Deschamps, J. R.; Parrish, D.; Shami, P. J.; Findlay, V. J.; Townsend, D. M.; Tew, K. D.; Singh, S.; Jia, L.; Ji, X.; Keefer, L. K. PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity. J. Med. Chem. 2006, 49, 1157-1164.
24. Findlay, V. J.; Townsend, D. M.; Saavedra, J. E.; Buzard, G. S.; Citro, M. L.; Keefer, L. K.; Ji, X.; Tew, K. D. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Mol. Pharmacol. 2004, 65, 1070-1079.
25. Townsend, D. M.; Findlay, V. J.; Fazilev, F.; Ogle, M.; Fraser, J.; Saavedra, J. E.; Ji, X.; Keefer, L. K.; Tew, K. D. A glutathione S-transferase π-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol. Pharmacol. 2006, 69, 501-508.
26. Armstrong, R. N. Glutathione S-transferases: reaction mechanism, structure, and function. Chem. Res. Toxicol. 1991, 4, 131-140.
27. Armstrong, R. N. Glutathione S-transferases: structure and mechanism of an archetypical detoxication enzyme. Adv. Enzymol. Relat. Areas Mol. Biol. 1994, 69, 1-44.
28. Armstrong, R. N. Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem. Res. Toxicol. 1997, 10, 2-18.
29. Giustarini, D.; Rossi, R.; Milzani, A.; Colombo, R.; Dalle-Donne, I. S-Glutathionylation: from redox regulation to human diseases. J. Cell. Mol. Med. 2008, 8, 201-212.
30. Ghezzi, P.; Di Simplicio, P. Glutathionylation pathways in drug response. Curr. Opin. Pharmacol. 2007, 7, 398-403.
31. Gallogly, M. M.; Mieyal, J. J. Mechanisms of reversible protein gluathionylation in redox signaling and oxidative stress. Curr. Opin. Pharmacol. 2007, 7, 381-391.
32. Tew, K. D. Redox in redux: emergent roles for glutathione Stransferase P (GSTP) in regulation of cell signaling and S-glutathionylation. Biochem. Pharmacol. 2007, 73, 1257-1269.
33. Dalle-Donne, I.; Rossi, R.; Giustarini, D.; Colombo, R.; Milzani, A. S-Glutathionylation in protein redox regulation. Free Radical Biol. Med. 2007, 43, 883-898.
34. Martinez-Ruiz, A.; Lamas, S. Signalling by NO-induced protein S-nitrosylation and S-glutathionylation: convergences and divergences. Cardiovasc. Res. 2007, 75, 220-228.
35. Dalle-Donne, I.; Milzani, A.; Gagliano, N.; Colombo, R.; Giustarini, D.; Rossi, R. Molecular mechanisms and potential clinical significance of S-glutathionylation. Antioxid. Redox Signaling 2008, 10, 445-473.
36. Chakrapani, H.; Wilde, T. C.; Citro, M. L.; Goodblatt, M. M.; Keefer, L. K.; Saavedra, J. E. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: structural analogues of PABA/NO, an anti-cancer lead compound. Bioorg. Med. Chem. 2008, 16, 2657-2664.
37. Wang, J.; Tekle, E.; Oubrahim, H.; Mieyal, J. J.; Stadtman, E. R.; Chock, P. B. Stable and controllable RNA interference: investigating the physiological function of glutathionylated actin. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5103-5106.
38. Wang, J.; Boja, E. S.; Tan, W.; Tekle, E.; Fales, H. M.; English, S.; Mieyal, J. J.; Chock, P. B. Reversible glutathionylation regulates actin polymerization in A431 cells. J. Biol. Chem. 2001, 276, 47763-47766.
39. Chakrapani, H.; Goodblatt, M. M.; Udupi, V.; Malaviya, S.; Shami, P. J.; Keefer, L. K.; Saavedra, J. E. Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound. Bioorg. Med. Chem. Lett. 2008, 18, 950-953.
40. - as nucleophile and leaving group in SNAr reactions. J. Org. Chem. 2001, 66, 3090-3098.
41. Drago, R. S.; Karstetter, B. R. The reaction of nitrogen(II) oxide with various primary and secondary amines. J. Am. Chem. Soc. 1961, 83, 1819-1822.
42. Saavedra, J. E.; Booth, M. N.; Hrabie, J. A.; Davies, K. M.; Keefer, L. K. Piperazine as a linker for incorporating the nitric oxide-releasing diazeniumdiolate group into other biomedically relevant functional molecules. J. Org. Chem. 1999, 64, 5124-5131.
43. Chakrapani, H.; Showalter, B. M.; Citro, M. L.; Keefer, L. K.; Saavedra, J. E. Nitric oxide prodrugs: diazeniumdiolate anions of hindered secondary amines. Org. Lett. 2007, 9, 4551-4554.
44. Saavedra, J. E.; Billiar, T. R.; Williams, D. L.; Kim, Y.-M.; Watkins, S. C.; Keefer, L. K. Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-α- induced apoptosis and toxicity in the liver. J. Med. Chem. 1997, 40, 1947-1954.
45. Chakrapani, H.; Showalter, B. M.; Kong, L.; Keefer, L. K.; Saavedra, J. E. V-PROLI/NO, a prodrug of the nitric oxide donor, PROLI/NO. Org. Lett. 2007, 9, 3409-3412.